Shuttle Pharmaceuticals faces an existential financial challenge as its pre-revenue clinical-stage model continues to generate significant quarterly operating losses, peaking at $3.9M in 2025Q2.
Price trend, volume and key moving averages
Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 24, 2026 | -$3.84 vs — | — vs — |
Q2 2026 May 15, 2026 | -$4.30 vs — | — vs — |
Q2 2026 Apr 1, 2026 | -$12.90 vs — | — vs — |
Q4 2025 Nov 13, 2025 | -$1.05 vs — | — vs — |
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH - Get Free Report) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 21,975 shares, a decrease of 44.1% from the August 31st total of 39,331 shares. Approximately 3.5% of the company's shares are short sold. Based on
Gaithersburg, Maryland--(Newsfile Corp. - August 28, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) (the "Company" or "Shuttle"), today announced that the Company is not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) as a result of its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 with the Securities and Exchange Commission by the required due date. The Company intends to file the Form 10-Q as soon as practicable.
Benchmark SHPH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.59 | $5.67M | -0.55 | — | — | -156.78% | — | |
| $8.59 | $359.01M | -4.54 | 56.89% | -225.34% | -165.83% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $7.15 | $297.74M | 21.19 | 10.37% | 20.98% | — | — | |
| $1.43 | $44.87M | 3.97 | — | 32.23% | 83.42% | — | |
| $66.79 | $3.26B | -14.39 | — | — | -1522.54% | — |
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Sep 16, 2026·SEC
Sep 11, 2026·SEC
Sep 2, 2026·SEC
Get notified when SHPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) stock FAQ — growth, dividends, profitability & financials explained
No. Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported a net loss of $10.3M over the trailing twelve months.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) had a return on equity (ROE) of -156.8% over the trailing twelve months. A negative ROE means the company lost money over the period.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) had negative free cash flow of $6.5M over the trailing twelve months.
